New chemo rotation aims to outsmart pancreatic cancer
NCT ID NCT07163273
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 36 times
Summary
This phase 2 trial tests a new approach for people with metastatic pancreatic cancer: monthly switching between two standard chemotherapy regimens, NALIRIFOX and GnP. The goal is to see if this alternating schedule can keep the cancer from growing longer than usual. About 41 participants will receive the treatment, and researchers will track how many are still alive without their cancer getting worse after 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Imbert Cancer Center
RECRUITINGBay Shore, New York, 11706, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Long Island Jewish Medical Center
RECRUITINGNew Hyde Park, New York, 11040, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Manhattan Eye, Ear and Throat Hospital
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NHPP Medical Oncology at Rego Park
RECRUITINGRego Park, New York, 11374, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Northern Westchester Cancer Center
RECRUITINGMount Kisco, New York, 10549, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Phelps Cancer Center
RECRUITINGSleepy Hollow, New York, 10591, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zuckerberg Cancer Center
RECRUITINGNew Hyde Park, New York, 11042, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
chemotherapy (NALIRIFOX and gemcitabine/nab-paclitaxel)
What this could lead to
If it works, this could offer a new way to slow pancreatic cancer growth and extend the time before the disease worsens.
What could go wrong
This is a small, early-phase trial with only 41 participants and no comparison group. The alternating regimen may cause more side effects and might not work better than standard treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.